Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
technetium-99m fibroblast growth factor 2
- Development stage
- Preclinical
- Lead developer
- Sapienza University of Rome
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Technetium-99m fibroblast growth factor 2 (99mTc-FGF2) is a radiolabeled recombinant human fibroblast growth factor 2 (hrFGF2) conjugated with the heterobifunctional chelator 6-hydrazinonicotinamide (HYNIC) and labeled with the gamma-emitting radioisotope technetium-99m [EP-538]. It is being developed as a diagnostic radiopharmaceutical for the early detection of cancer metastases and imaging of tumor-associated fibroblasts (TAFs). 99mTc-FGF2 specifically targets fibroblast growth factor receptor 2 (FGFR2), particularly the FGFR2c isoform, which is overexpressed during the epithelial-mesenchymal transition (EMT) in early-stage tumors [EP-538].
- Other names
- 99mTc-FGF299mTc-HYNIC-FGF2technetium-99m fibroblast growth factor-2technetium99m fibroblast growth factor-2technetium 99m fibroblast growth factor-2technetium-99m-labeled fibroblast growth factor 2technetium99m-labeled fibroblast growth factor 2technetium 99m-labeled fibroblast growth factor 2technetium-99m-labeled recombinant human fibroblast growth factor 2technetium99m-labeled recombinant human fibroblast growth factor 2technetium 99m-labeled recombinant human fibroblast growth factor 2
02
Targets
FGFR2 (Keratinocyte growth factor receptor)
Beyond the preview
Go deeper on technetium-99m fibroblast growth factor 2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on technetium-99m fibroblast growth factor 2.